Abstract

Poorly crystalline hydroxyapatite was improved so that it has better cell affinity in vitro. We studied the efficacy of a novel resorbable poorly crystalline hydroxyapatite-based biphasic calcium phosphate, BonaGraft, for bone regeneration in vivo. The beagle was used as an animal model, and cylindrical artificial bone defects (3 mm in diameter and 6 mm long) were produced in the alveolar bone. The BonaGraft (ratio of poorly crystalline hydroxyapatite to b-tricalcium phosphate, 60:40) was used to fill in the defect, and unfilled defects served as a control group. At 5, 8 and 10 weeks after the operation, the size of the residual graft and new bone formation were evaluation by a histomorphometric analysis. In a clinical trial, 33 enrolled patients included 15 males and 18 females with ages ranging from 35 to 54 years. The main indications were ridge augmentation (n = 12), sinus lifting (n = 2), repair of periodontal disease (n= 14), and repair of radicular cysts (n= 5). The clinical outcomes of the surgery were primarily evaluated by clinical radiographs. In the animal study, implanting BonaGraft produced greater new-bone formation (74.5 ± 1.0) at 10 weeks postoperatively than that of the control (40.2 ± 0.3). BonaGraft particles were gradually resorbed and substituted by bone. The in vivo graft resorption time and bone healing time of 12.1 weeks were mathematically determined by the least squares method. In the clinical test, all patients implanted with BonaGraft reported satisfactory clinical outcomes without major material-related side effects. According to the radiographic pictures, implantation of BonaGraft enhanced bone formation. According to the animal study results, BonaGraft has a suitable resorption period and satisfactory outcomes of new bone formation. The clinical study produced high satisfaction with clinical results both objectively and subjectively. For this reason, BonaGraft seems to be an alternative choice for a bone substitute in dental applications. © 2010 Association for Dental Sciences of The Republic of China.
Original languageEnglish
Pages (from-to)100-108
Number of pages9
JournalJournal of Dental Sciences
Volume5
Issue number2
DOIs
Publication statusPublished - 2010

Fingerprint

Bone Substitutes
Durapatite
Osteogenesis
Tooth
Bone and Bones
Radicular Cyst
Transplants
Bone Regeneration
Periodontal Diseases
Bone Resorption
Least-Squares Analysis
Taiwan
Animal Models
Clinical Trials
Control Groups
hydroxyapatite-beta tricalcium phosphate

Keywords

  • β-tricalcium phosphate
  • Biphasic calcium phosphate
  • Poorly crystalline hydroxyapatite

Cite this

@article{edf5b053f380480dbea14dd6c3b18259,
title = "In vivo evaluation of poorly crystalline hydroxyapatite-based biphasic calcium phosphate bone substitutes for treating dental bony defects",
abstract = "Poorly crystalline hydroxyapatite was improved so that it has better cell affinity in vitro. We studied the efficacy of a novel resorbable poorly crystalline hydroxyapatite-based biphasic calcium phosphate, BonaGraft, for bone regeneration in vivo. The beagle was used as an animal model, and cylindrical artificial bone defects (3 mm in diameter and 6 mm long) were produced in the alveolar bone. The BonaGraft (ratio of poorly crystalline hydroxyapatite to b-tricalcium phosphate, 60:40) was used to fill in the defect, and unfilled defects served as a control group. At 5, 8 and 10 weeks after the operation, the size of the residual graft and new bone formation were evaluation by a histomorphometric analysis. In a clinical trial, 33 enrolled patients included 15 males and 18 females with ages ranging from 35 to 54 years. The main indications were ridge augmentation (n = 12), sinus lifting (n = 2), repair of periodontal disease (n= 14), and repair of radicular cysts (n= 5). The clinical outcomes of the surgery were primarily evaluated by clinical radiographs. In the animal study, implanting BonaGraft produced greater new-bone formation (74.5 ± 1.0) at 10 weeks postoperatively than that of the control (40.2 ± 0.3). BonaGraft particles were gradually resorbed and substituted by bone. The in vivo graft resorption time and bone healing time of 12.1 weeks were mathematically determined by the least squares method. In the clinical test, all patients implanted with BonaGraft reported satisfactory clinical outcomes without major material-related side effects. According to the radiographic pictures, implantation of BonaGraft enhanced bone formation. According to the animal study results, BonaGraft has a suitable resorption period and satisfactory outcomes of new bone formation. The clinical study produced high satisfaction with clinical results both objectively and subjectively. For this reason, BonaGraft seems to be an alternative choice for a bone substitute in dental applications. {\circledC} 2010 Association for Dental Sciences of The Republic of China.",
keywords = "β-tricalcium phosphate, Biphasic calcium phosphate, Poorly crystalline hydroxyapatite",
author = "M.-S. Huang and Wu, {Hong Da} and N.-C. Teng and B.-Y. Peng and Wu, {Jia Yo} and W.-J. Chang and J.-C. Yang and C.-C. Chen and S.-Y. Lee",
note = "被引用次數:8 Export Date: 23 August 2016 通訊地址: Chen, C.-C.; Graduate Institute of Biomedical Materials and Engineering, College of Oral Medicine, Taipei Medical University, 250, Wu-Hsing Street, Taipei 11042, Taiwan; 電子郵件: polyjack@tmu.edu.tw 參考文獻: Ilan, D.I., Ladd, A.L., Bone graft substitutes (2003) Oper Tech Plast Reconstr Surg, 9, pp. 151-160; Williams, A., Szabo, R.M., Bone transplantation (2004) Orthopedics, 27, pp. 488-495; Garg, A.K., (2004) Bone Biology, Harvesting, Drafting for Dental Implant; Rationale and Clinical Applications, , Quintessence Chicago; Rack, A., Knabe, C., Stiller, M., Synchrotron-tomography for Evaluation of Bone Tissue Regeneration Using Rapidly Re-sorbable Bone Substitute Materials. E-J Destr Test, 2006; 11, , Availableat:http://www.ndt.net/article/ecndt2006/doc/Th.1.2.2.pdf; Knabe, C., Houshmand, A., Berger, G., Effect of rapidly resorbable bone substitute materials on the temporal expression of the osteoblastic phenotype in vitro (2008) J Biomed Mater Res A, 84, pp. 856-868; Branemark, P.I., Osseointegration and its experimental background (1983) J Prosthet Dent, 50, pp. 399-410; Jalota, S., Bhaduri, S.B., Tas, A.C., In vitro testing of calcium phosphate (HA, TCP, and biphasic HA-TCP) whiskers (2006) J Biomed Mater Res A, 78, pp. 481-490; Nery, E.B., Legeros, R.Z., Lynch, K.L., Lee, K., Tissue response to biphasic calcium phosphate ceramic with different ratios of HA/beta TCP in periodontal osseous defects (1992) J Periodontol, 63, pp. 729-735; Legeros, R.Z., Calcium phosphate-based osteoinductive materials (2008) Chem Rev, 108, pp. 4742-4753; Szabo, G., Huys, L., Coulthard, P., A prospective multi-center randomized clinical trial of autogenous bone versus beta-tricalcium phosphate graft alone for bilateral sinus elevation: Histologic and histomorphometric evaluation (2005) Int J Oral Maxillofac Implants, 20, pp. 371-381; Pearce, A.I., Richards, R.G., Milz, S., Schneider, E., Pearce, S.G., Animal models for implant biomaterial research in bone: A review (2007) Eur Cell Mater, 13, pp. 1-10; Tamai, N., Myoui, A., Tomita, T., Novel hydroxyapatite ceramics with an interconnective porous structure exhibit superior osteoconduction in vivo (2002) J Biomed Mater Res, 59, pp. 110-117; Jin, Q.M., Takita, H., Kohgo, T., Atsumi, K., Itoh, H., Kuboki, Y., Effects of geometry of hydroxyapatite as a cell substratum in BMP-induced ectopic bone formation (2000) J Biomed Mater Res, 52, pp. 491-499; Oonishi, H., Hench, L.L., Wilson, J., Comparative bone growth behavior in granules of bioceramic materials of various sizes (1999) J Biomed Mater Res, 44, pp. 31-43; Tischler, M., Misch, C.E., Extraction site bone grafting in general dentistry: Review of applications and principles (2004) Dent Today, 23, pp. 1-7; Yamamichi, N., Itose, M., (2008) Sinus Floor Elevation, pp. 18-20. , Quintessence Tokyo; Jung, Y.S., Lee, S.H., Park, H.S., Decompression of large odontogenic keratocysts of the mandible (2005) J Oral Maxillofac Surg, 63, pp. 267-271; Horch, H.H., Sader, R., Pautke, C., Neff, A., Deppe, H., Kolk, A., Synthetic, pure-phase beta-tricalcium phosphate ceramic granules (Cerasorb) for bone regeneration in the reconstructive surgery of the jaws (2006) Int J Oral Maxillofac Surg, 35, pp. 708-713; Sun, W., Zhang, F., Guo, J., Wu, J., Wu, W., Effects of amorphous calcium phosphate on periodontal ligament cell adhesion and proliferation in vitro (2008) J Med Biol Eng, 28, pp. 107-112",
year = "2010",
doi = "10.1016/S1991-7902(10)60014-1",
language = "English",
volume = "5",
pages = "100--108",
journal = "Journal of Dental Sciences",
issn = "1991-7902",
publisher = "中華牙醫學會",
number = "2",

}

TY - JOUR

T1 - In vivo evaluation of poorly crystalline hydroxyapatite-based biphasic calcium phosphate bone substitutes for treating dental bony defects

AU - Huang, M.-S.

AU - Wu, Hong Da

AU - Teng, N.-C.

AU - Peng, B.-Y.

AU - Wu, Jia Yo

AU - Chang, W.-J.

AU - Yang, J.-C.

AU - Chen, C.-C.

AU - Lee, S.-Y.

N1 - 被引用次數:8 Export Date: 23 August 2016 通訊地址: Chen, C.-C.; Graduate Institute of Biomedical Materials and Engineering, College of Oral Medicine, Taipei Medical University, 250, Wu-Hsing Street, Taipei 11042, Taiwan; 電子郵件: polyjack@tmu.edu.tw 參考文獻: Ilan, D.I., Ladd, A.L., Bone graft substitutes (2003) Oper Tech Plast Reconstr Surg, 9, pp. 151-160; Williams, A., Szabo, R.M., Bone transplantation (2004) Orthopedics, 27, pp. 488-495; Garg, A.K., (2004) Bone Biology, Harvesting, Drafting for Dental Implant; Rationale and Clinical Applications, , Quintessence Chicago; Rack, A., Knabe, C., Stiller, M., Synchrotron-tomography for Evaluation of Bone Tissue Regeneration Using Rapidly Re-sorbable Bone Substitute Materials. E-J Destr Test, 2006; 11, , Availableat:http://www.ndt.net/article/ecndt2006/doc/Th.1.2.2.pdf; Knabe, C., Houshmand, A., Berger, G., Effect of rapidly resorbable bone substitute materials on the temporal expression of the osteoblastic phenotype in vitro (2008) J Biomed Mater Res A, 84, pp. 856-868; Branemark, P.I., Osseointegration and its experimental background (1983) J Prosthet Dent, 50, pp. 399-410; Jalota, S., Bhaduri, S.B., Tas, A.C., In vitro testing of calcium phosphate (HA, TCP, and biphasic HA-TCP) whiskers (2006) J Biomed Mater Res A, 78, pp. 481-490; Nery, E.B., Legeros, R.Z., Lynch, K.L., Lee, K., Tissue response to biphasic calcium phosphate ceramic with different ratios of HA/beta TCP in periodontal osseous defects (1992) J Periodontol, 63, pp. 729-735; Legeros, R.Z., Calcium phosphate-based osteoinductive materials (2008) Chem Rev, 108, pp. 4742-4753; Szabo, G., Huys, L., Coulthard, P., A prospective multi-center randomized clinical trial of autogenous bone versus beta-tricalcium phosphate graft alone for bilateral sinus elevation: Histologic and histomorphometric evaluation (2005) Int J Oral Maxillofac Implants, 20, pp. 371-381; Pearce, A.I., Richards, R.G., Milz, S., Schneider, E., Pearce, S.G., Animal models for implant biomaterial research in bone: A review (2007) Eur Cell Mater, 13, pp. 1-10; Tamai, N., Myoui, A., Tomita, T., Novel hydroxyapatite ceramics with an interconnective porous structure exhibit superior osteoconduction in vivo (2002) J Biomed Mater Res, 59, pp. 110-117; Jin, Q.M., Takita, H., Kohgo, T., Atsumi, K., Itoh, H., Kuboki, Y., Effects of geometry of hydroxyapatite as a cell substratum in BMP-induced ectopic bone formation (2000) J Biomed Mater Res, 52, pp. 491-499; Oonishi, H., Hench, L.L., Wilson, J., Comparative bone growth behavior in granules of bioceramic materials of various sizes (1999) J Biomed Mater Res, 44, pp. 31-43; Tischler, M., Misch, C.E., Extraction site bone grafting in general dentistry: Review of applications and principles (2004) Dent Today, 23, pp. 1-7; Yamamichi, N., Itose, M., (2008) Sinus Floor Elevation, pp. 18-20. , Quintessence Tokyo; Jung, Y.S., Lee, S.H., Park, H.S., Decompression of large odontogenic keratocysts of the mandible (2005) J Oral Maxillofac Surg, 63, pp. 267-271; Horch, H.H., Sader, R., Pautke, C., Neff, A., Deppe, H., Kolk, A., Synthetic, pure-phase beta-tricalcium phosphate ceramic granules (Cerasorb) for bone regeneration in the reconstructive surgery of the jaws (2006) Int J Oral Maxillofac Surg, 35, pp. 708-713; Sun, W., Zhang, F., Guo, J., Wu, J., Wu, W., Effects of amorphous calcium phosphate on periodontal ligament cell adhesion and proliferation in vitro (2008) J Med Biol Eng, 28, pp. 107-112

PY - 2010

Y1 - 2010

N2 - Poorly crystalline hydroxyapatite was improved so that it has better cell affinity in vitro. We studied the efficacy of a novel resorbable poorly crystalline hydroxyapatite-based biphasic calcium phosphate, BonaGraft, for bone regeneration in vivo. The beagle was used as an animal model, and cylindrical artificial bone defects (3 mm in diameter and 6 mm long) were produced in the alveolar bone. The BonaGraft (ratio of poorly crystalline hydroxyapatite to b-tricalcium phosphate, 60:40) was used to fill in the defect, and unfilled defects served as a control group. At 5, 8 and 10 weeks after the operation, the size of the residual graft and new bone formation were evaluation by a histomorphometric analysis. In a clinical trial, 33 enrolled patients included 15 males and 18 females with ages ranging from 35 to 54 years. The main indications were ridge augmentation (n = 12), sinus lifting (n = 2), repair of periodontal disease (n= 14), and repair of radicular cysts (n= 5). The clinical outcomes of the surgery were primarily evaluated by clinical radiographs. In the animal study, implanting BonaGraft produced greater new-bone formation (74.5 ± 1.0) at 10 weeks postoperatively than that of the control (40.2 ± 0.3). BonaGraft particles were gradually resorbed and substituted by bone. The in vivo graft resorption time and bone healing time of 12.1 weeks were mathematically determined by the least squares method. In the clinical test, all patients implanted with BonaGraft reported satisfactory clinical outcomes without major material-related side effects. According to the radiographic pictures, implantation of BonaGraft enhanced bone formation. According to the animal study results, BonaGraft has a suitable resorption period and satisfactory outcomes of new bone formation. The clinical study produced high satisfaction with clinical results both objectively and subjectively. For this reason, BonaGraft seems to be an alternative choice for a bone substitute in dental applications. © 2010 Association for Dental Sciences of The Republic of China.

AB - Poorly crystalline hydroxyapatite was improved so that it has better cell affinity in vitro. We studied the efficacy of a novel resorbable poorly crystalline hydroxyapatite-based biphasic calcium phosphate, BonaGraft, for bone regeneration in vivo. The beagle was used as an animal model, and cylindrical artificial bone defects (3 mm in diameter and 6 mm long) were produced in the alveolar bone. The BonaGraft (ratio of poorly crystalline hydroxyapatite to b-tricalcium phosphate, 60:40) was used to fill in the defect, and unfilled defects served as a control group. At 5, 8 and 10 weeks after the operation, the size of the residual graft and new bone formation were evaluation by a histomorphometric analysis. In a clinical trial, 33 enrolled patients included 15 males and 18 females with ages ranging from 35 to 54 years. The main indications were ridge augmentation (n = 12), sinus lifting (n = 2), repair of periodontal disease (n= 14), and repair of radicular cysts (n= 5). The clinical outcomes of the surgery were primarily evaluated by clinical radiographs. In the animal study, implanting BonaGraft produced greater new-bone formation (74.5 ± 1.0) at 10 weeks postoperatively than that of the control (40.2 ± 0.3). BonaGraft particles were gradually resorbed and substituted by bone. The in vivo graft resorption time and bone healing time of 12.1 weeks were mathematically determined by the least squares method. In the clinical test, all patients implanted with BonaGraft reported satisfactory clinical outcomes without major material-related side effects. According to the radiographic pictures, implantation of BonaGraft enhanced bone formation. According to the animal study results, BonaGraft has a suitable resorption period and satisfactory outcomes of new bone formation. The clinical study produced high satisfaction with clinical results both objectively and subjectively. For this reason, BonaGraft seems to be an alternative choice for a bone substitute in dental applications. © 2010 Association for Dental Sciences of The Republic of China.

KW - β-tricalcium phosphate

KW - Biphasic calcium phosphate

KW - Poorly crystalline hydroxyapatite

UR - https://www.scopus.com/results/citedbyresults.uri?sort=plf-f&cite=2-s2.0-78649242597&src=s&imp=t&sid=aa2f4f8584a33331d4c6a6589c32e85c&sot=cite&sdt=a&sl=0&origin=recordpage&editSaveSearch=&txGid=f8dd1edad11ad71b9aff74661529d6a2

U2 - 10.1016/S1991-7902(10)60014-1

DO - 10.1016/S1991-7902(10)60014-1

M3 - Article

VL - 5

SP - 100

EP - 108

JO - Journal of Dental Sciences

JF - Journal of Dental Sciences

SN - 1991-7902

IS - 2

ER -